Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (3): 259-265.doi: 10.3969/j.issn.1000-6621.2020.03.015
• Original Articles • Previous Articles Next Articles
GAO Tian-hui1,SHU Wei2,GAO Jing-tao2,LU Yu1(),LI Qi2()
Received:
2019-11-06
Online:
2020-03-10
Published:
2020-03-18
Contact:
Yu LU,Qi LI
E-mail:luyu4876@hotmail.com;lq0703@hotmail.com
GAO Tian-hui,SHU Wei,GAO Jing-tao,LU Yu,LI Qi. Analysis of clarithromycin resistance and its influencing factors in 254 patients with drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(3): 259-265. doi: 10.3969/j.issn.1000-6621.2020.03.015
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.03.015
药品 | 耐药肺结核患者(254例) | MDR/XDR-TB组(229例) | MR-TB组(25例) | |||
---|---|---|---|---|---|---|
例数 | 耐药率(%) | 例数 | 耐药率(%) | 例数 | 耐药率(%) | |
Clr | 17 | 6.69 | 17 | 7.42 | 0 | 0.00 |
Lfx | 94 | 37.01 | 94 | 41.05 | 0 | 0.00 |
Mfx | 32 | 12.60 | 32 | 13.97 | 0 | 0.00 |
Cfz | 33 | 12.99 | 33 | 14.41 | 0 | 0.00 |
EMB | 104 | 40.94 | 102 | 44.54 | 2 | 8.00 |
Am | 55 | 21.65 | 55 | 24.02 | 0 | 0.00 |
Sm | 198 | 77.95 | 198 | 86.46 | 0 | 0.00 |
Pto | 50 | 19.69 | 50 | 21.83 | 0 | 0.00 |
PAS | 89 | 35.04 | 89 | 38.86 | 0 | 0.00 |
Pa | 127 | 50.00 | 127 | 55.46 | 0 | 0.00 |
Km | 59 | 23.23 | 59 | 25.76 | 0 | 0.00 |
Cm | 74 | 29.13 | 74 | 32.31 | 0 | 0.00 |
RFP | 218 | 85.83 | 211 | 92.14 | 7 | 28.00 |
Rpt | 226 | 88.98 | 217 | 94.76 | 9 | 36.00 |
Rfb | 197 | 77.56 | 190 | 82.97 | 7 | 28.00 |
INH | 243 | 95.67 | 229 | 100.00 | 14 | 56.00 |
药品 | Clr敏感组(212例) | Clr耐药组(17例) | χ2值 | P值 |
---|---|---|---|---|
Lfx | 84(39.62) | 10(58.82) | 2.398 | 0.122 |
Mfx | 24(11.32) | 8(47.06) | 16.721 | <0.01 |
Cfz | 21(9.91) | 12(70.59) | 46.987 | <0.01 |
EMB | 88(41.51) | 14(82.35) | 10.628 | 0.001 |
Pto | 47(22.17) | 3(17.65) | 0.017 | 0.897 |
Am | 46(21.70) | 9(52.94) | 6.793 | 0.009 |
Sm | 183(86.32) | 15(88.24) | 0.000 | 1.000 |
PAS | 76(35.85) | 13(76.47) | 10.930 | 0.001 |
Pa | 112(52.83) | 15(88.24) | 7.986 | 0.005 |
Km | 50(23.58) | 8(47.06) | 3.428 | 0.072 |
Cm | 61(28.77) | 13(76.47) | 16.370 | <0.01 |
临床因素 | Clr敏感组(212例) | Clr耐药组(17例) | χ2值 | P值 | ||||
---|---|---|---|---|---|---|---|---|
性别 | 1.168 | 0.377 | ||||||
男 | 162(76.42) | 11(64.71) | ||||||
女 | 50(23.58) | 6(35.29) | ||||||
年龄组(岁) | -0.932 | 0.351 | ||||||
16~ | 40(18.88) | 6(35.30) | ||||||
26~ | 49(23.11) | 2(11.76) | ||||||
36~ | 25(11.79) | 3(17.65) | ||||||
46~ | 49(23.11) | 2(11.76) | ||||||
≥56 | 49(23.11) | 4(23.53) | ||||||
病程(月) | 0.136 | 0.712 | ||||||
≤36 | 122(57.55) | 9(52.94) | ||||||
>36 | 90(42.45) | 8(47.06) | ||||||
耐药数目(个) | 12.711 | <0.001 | ||||||
≤7 | 120(56.60) | 2(11.76) | ||||||
>7 | 92(43.40) | 15(88.24) | ||||||
BMI | -1.048 | 0.295 | ||||||
无数据 | 15(7.07) | 1(5.88) | ||||||
<18.50 | 57(26.89) | 7(41.18) | ||||||
18.50~ | 115(54.25) | 8(47.06) | ||||||
≥25.00 | 25(11.79) | 1(5.88) | ||||||
临床因素 | Clr敏感组(212例) | Clr耐药组(17例) | χ2值 | P值 | ||||
吸烟史 | 0.124 | 0.801 | ||||||
无 | 128(60.38) | 11(64.71) | ||||||
有 | 84(39.62) | 6(35.29) | ||||||
并发病毒性肝炎 | 13(6.13) | 4(23.53) | 6.931 | 0.027 | ||||
患者类型 | 0.293 | 0.769 | ||||||
初治 | 50(23.58) | 5(29.41) | ||||||
复治 | 162(76.42) | 12(70.59) | ||||||
既往Clr治疗史 | 0.138 | 0.756 | ||||||
有 | 32(15.09) | 2(11.76) | ||||||
无 | 180(84.91) | 15(88.24) | ||||||
痰GeneXpert-rpoB突变结果 | 2.515 | 0.133 | ||||||
有 | 188(88.68) | 14(82.35) | ||||||
无 | 24(11.32) | 3(17.65) | ||||||
CT扫描显示是否有空洞 | 1.798 | 0.180 | ||||||
有 | 114(53.77) | 12(70.59) | ||||||
无 | 98(46.23) | 5(29.41) |
[1] | Global tuberculosis report 2019. Global tuberculosis report 2019. Genenva:World Health Organization, 2019. |
[2] | Global tuberculosis report 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO/CDS/TB/2019.7. Geneva: World Health Organization, 2019. |
[3] | Global tuberculosis report 2019. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014. |
[4] | Global tuberculosis report 2019. Treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/2016.04. Geneva: World Health Organization, 2016. |
[5] | Bolhuis MS, van der Laan T, Kosterink JG , et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. Eur Respir J, 2014,44(3):808-811. |
[6] | Cavalieri SJ, Biehle JR, Sanders WJ . Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1995,39(7):1542-1545. |
[7] | 陆宇, 王彬, 赵伟杰 , 等. 氯法齐明与其他抗结核药物联用对结核分枝杆菌的作用. 中华结核和呼吸杂志, 2010,33(9):675-678. |
[8] | Falzari K, Zhu Z, Pan D , et al. In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2005,49(4):1447-1454. |
[9] | van der Paardt AF, Wilffert B, Akkerman OW , et al. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur Respir J, 2015,46(2):444-455. |
[10] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09. |
[11] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017结核病分类. 2017-11-09. |
[12] | 赵雁林, 逄宇 . 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 59-65. |
[13] | Global tuberculosis report 2019. Definitions and reporting framework for tuberculosis-2013 revision. Geneva: World Health Organization, 2013. |
[14] | 李君莲, 张敬蕊, 李桂莲 , 等. 新疆地区93株耐多药结核分枝杆菌耐药情况分析. 中国预防医学杂志, 2012,13(9):645-649. |
[15] | 邝小佳, 邝浩斌, 蔡杏珊 , 等. 广州地区5年间耐多药结核分枝杆菌药物敏感试验结果分析. 临床肺科杂志, 2016,21(1):10-12. |
[16] | 贾芳, 宋青山, 黄海荣 . 某医院广泛耐药结核病住院患者耐药特点及危险因素分析. 中华疾病控制杂志, 2019,23(3):336-340. |
[17] | 李影, 张东浩 . 531株结核分枝杆菌的药敏分析. 中国医药指南, 2015,13(26):156-157. |
[18] | Morris RP, Nguyen L, Gatfield J , et al. Ancestral Antibiotic Resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A, 2005,102(34):12200-12205. |
[19] | Warit S, Phunpruch S, Jityam C , et al. Genetic characterisation of a whiB7 mutant of a Mycobacterium tuberculosis clinical strain. J Glob Antimicrob Resist, 2015,3(4):262-266. |
[20] | Buriánková K, Doucet-Populaire F, Dorson O , et al. Molecular Basis of Intrinsic Macrolide Resistance in the Mycobacterium tuberculosis Complex. Antimicrob Agents Chemother, 2004,48(1):143-150. |
[21] | Phunpruch S, Warit S, Suksamran R , et al. A role for 16S rRNA dimethyltransferase (ksgA) in intrinsic clarithromycin resistance in Mycobacterium tuberculosis. Int J Antimicrob Agents, 2013,41(6):548-551. |
[22] | Danilchanka O, Pires D, Anes E , et al. The Mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules. Antimicrob Agents Chemother, 2015,59(4):2328-2336. |
[23] | Vester B, Douthwaite S . Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother, 2001,45(1):1-12. |
[24] | Pang Y, Zhu D, Zheng H , et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis, 2017,17(1):711. |
[25] | Pule CM, Sampson SL, Warren RM , et al. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother, 2016,71(1):17-26. |
[26] | Te Brake LHM, de Knegt GJ, de Steenwinkel JE , et al. The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. Annu Rev Pharmacol Toxicol, 2018,58:271-291. |
[27] | Moore RA, DeShazer D, Reckseidler S , et al. Efflux-Mediated Aminoglycoside and Macrolide Resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother, 1999,43(3):465-470. |
[28] | Alame-Emane AK, Xu P, Pierre-Audigier C , et al. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Int J Tuberc Lung Dis, 2015,19(6):679-684. |
[29] | Xianyu J, Feng J, Yang Y , et al. Correlation of oxidative stress in patients with HBV-induced liver disease with HBV genotypes and drug resistance mutations. Clin Biochem, 2018,55:21-27. |
[30] | Dharmaraja AT . Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria. J Med Chem, 2017,60(8):3221-3240. |
[31] | Yew WW, Chan DP, Chang KC , et al. Does oxidative stress contribute to antituberculosis drug resistance?. J Thorac Dis, 2019,11(7):E100-102. |
[32] | Amábile-Cuevas CF . Antibiotic Resistance: From Darwin to Lederberg to Keynes. Microb Drug Resist, 2013,19(2):73-87. |
[33] | O’Sullivan DM, McHugh TD, Gillespie SH . The effect of oxidative stress on the mutation rate of Mycobacterium tuberculosis with impaired catalase/peroxidase function. J Antimicrob Chemother, 2008,62(4):709-712. |
[34] | Rastogi N, Labrousse V . Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother, 1991,35(3):462-470. |
[35] | Bhusal Y, Shiohira CM, Yamane N . Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents, 2005,26(4):292-297. |
[36] | Mor N, Esfandiari A . Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother, 1997,41(9):2035-2036. |
[37] | 李琦, 姜晓颖, 高孟秋 , 等. 18个月化疗方案对耐多药肺结核患者的治疗效果分析. 中国防痨杂志, 2019,41(3):294-301. |
[38] | Van der Paardt AL, Akkerman OW, Gualano G , et al. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. Eur Respir J, 2017,49(3):1601612. |
[1] | LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008. |
[2] | Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893. |
[3] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[4] | ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[8] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[9] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[10] | LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941. |
[11] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[12] | DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955. |
[13] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[14] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[15] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||